Contact Us  |  Site Map  |  Search  
 
 
Boston Millennia Partners
   
  Boston Millennia Partners provides private equity financing to high growth companies in the healthcare, life sciences, telecommunications, and information technology industries. Our team brings over one hundred years of combined private equity experience to the investment process. Our broad experience, combined with expertise in finance; operations; engineering; life sciences research and development; partnering with pharmaceutical companies; business development; executive recruiting; and law provides significant value to the companies in which we invest. The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million.  
   
   

PAREXEL Hits New Peak Market Cap of $1.6 Billion
A. Dana Callow, Jr. is pleased to highlight that, as a result of the company’s better-than-expected fiscal 2nd-quarter results, shares of Parexel International Corporation (PRXL) traded at an all time high on January 24, 2008, reaching a peak price of $58.38 and a market value of over $1.6 billion.

Learn More >

Collegium's Partner, BTG, Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnea Patients
Collegium announced that its licensing partner, BTG, reports positive results from the clinical proof of concept study of BGC20-0166, a combination of two marketed drugs for the treatment of obstructive sleep apnea syndrome.

Learn More >

Collegium Pharmaceutical Announces FDA Filing for AllerNase™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
Collegium announced that it filed a Supplemental New Drug Application with the FDA for the approval of AllerNase™ Nasal Spray, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis.

Learn More >

EPIX Pharmaceuticals Expands Collaboration with Cystic Fibrosis Foundation Therapeutics
EPIX Pharmaceuticals, Inc. announced that it has expanded its collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation.

Learn More >

MedAptus’ Facility Charge Capture and Infusion Services Module Purchased by M. D. Anderson Cancer Center
MedAptus®, the leading provider of point-of-care charge capture technologies, today announced that its customer, The University of Texas M. D. Anderson Cancer Center, is implementing the company’s Facility Charge Capture and Infusion Services Module solutions.

Learn More >

MedAptus Experiences Record Growth of 70 Percent
MedAptus®, the leading provider of point-of-care charge capture technologies, today announced a 70 percent increase in year-over-year revenue for 2007.

Learn More >

Vertellus Finalizes New Contract with Odyssey Logistics & Technology
Odyssey Logistics & Technology Corporation announced that Vertellus Specialties Inc. (Vertellus) has signed a three-year agreement to outsource its North American transportation and logistics operations, including global imports and exports to Odyssey.

Learn More >

CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis
CombinatoRx announced top line results of its randomized, blinded, placebo-controlled Phase 2 proof-of-concept clinical trial of CRx-191 in plaque psoriasis. CRx-191 is a topical synergistic combination drug candidate in development for psoriasis and other steroid-responsive dermatoses.

Learn More >

Odyssey Logistics & Technology Expands to Europe; Opens New Opportunities for Clients
Odyssey Logistics & Technology Corporation announces the opening of its European office in Antwerp, Belgium. Odyssey Logistics Europe BVBA will be located at Haven 1053, Nieuwe Weg 1, B-2070 Zwijndrecht, Belgium.

Learn More >

CombinatoRx Granted Broad Patent Covering TCA-Glucocorticoid Combinations
CombinatoRx announced that it has been granted a United States patent (# 7,335,371) entitled "Combinations for the treatment of inflammatory disorders" with broad composition of matter and method of use claims covering combinations of tricyclic antidepressants (TCA) and glucocorticosteroids.

Learn More >

 
 
Click Here to receive news updates from Boston Millennia Partners >


 
CEO Video NECN CEO Corner Interview With Dana Callow

Video: Large | Small
CEO Video Dana Callow on PBS’s Greater Boston With Emily Rooney

Video: Large | Small
spacer
   
Healthcare information is becoming broadly available to consumers, which is expanding basic demand.
Learn More >
 
   
Three key areas of opportunity in the Life Sciences sector are drug discovery & development...
Learn More >
 
   
In the new world of technology, voice, video and data converge. With the emergence of broadband...
Learn More >
 
   
Driven by advances in computer science, hardware, and software technology, and by the adoption of...
Learn More >
 
 
  | Our Firm      Our Team      Our Portfolio      Resources      News  
  © 2007 Boston Millennia Partners  All Rights Reserved BMP Extranet »